These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 2570399)
1. Detectability of thyroid anti-microsomal antibodies, changes in thyroid-stimulating immunoglobulins (TSI) and thyrotropin-binding-inhibiting immunoglobulins (TBII) during methimazole treatment of Graves' disease patients. Szabó J; Leövey A; Karányi Z; Várvölgyi C; Fórizs E; Herceg L Acta Med Hung; 1989; 46(1):23-30. PubMed ID: 2570399 [TBL] [Abstract][Full Text] [Related]
2. [Clinical relevance of the determination of TSH-binding inhibitory immunoglobulins (TBII) in patients with immunogenic hyperthyroidism in methimazole therapy]. Heberling HJ; Bierwolf B; Kuhlmann E; Klugmann T; Dietel P; Fischer S Dtsch Z Verdau Stoffwechselkr; 1987; 47(6):331-6. PubMed ID: 2896115 [TBL] [Abstract][Full Text] [Related]
3. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084 [TBL] [Abstract][Full Text] [Related]
4. Detection of tsh binding inhibiting antibodies (TBI-ab) and thyroid adenylate cyclase stimulating antibodies (TS-ab) in sera of patients with Graves' disease. Lattanzi V; Scardapane R; Ciampolillo A; Vincenti C; Giorgino R Boll Soc Ital Biol Sper; 1985 Jan; 61(1):55-60. PubMed ID: 3838478 [TBL] [Abstract][Full Text] [Related]
5. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965 [TBL] [Abstract][Full Text] [Related]
6. Clinical experience with a radioreceptor assay for TSH-binding inhibiting immunoglobulins (TBII). Heberling HJ; Bierwolf B; Lohmann D Exp Clin Endocrinol; 1988 Aug; 91(3):355-61. PubMed ID: 2908034 [TBL] [Abstract][Full Text] [Related]
7. Partial characterization and clinical correlation of circulating human immunoglobulins directed against thyrotrophin binding sites in guinea pig fat cell membranes. Development of a direct enzyme immunoassay. Baker JR; Lukes YG; Smallridge RC; Berger M; Burman KD J Clin Invest; 1983 Oct; 72(4):1487-97. PubMed ID: 6138364 [TBL] [Abstract][Full Text] [Related]
8. Graves' disease: evolution and prognosis after eight months of treatment with methimazole. Gauna AT; Guillén CE; Sartorio GC; Soto RJ Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158 [TBL] [Abstract][Full Text] [Related]
9. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939 [TBL] [Abstract][Full Text] [Related]
10. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs. Wenzel KW; Lente JR J Clin Endocrinol Metab; 1984 Jan; 58(1):62-9. PubMed ID: 6196375 [TBL] [Abstract][Full Text] [Related]
11. Prediction of remission after antithyroid drug treatment in Graves' disease. Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease. Hörmann R; Saller B; Müller R; Mann K Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149 [TBL] [Abstract][Full Text] [Related]
13. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods. Morris JC; Hay ID; Nelson RE; Jiang NS Mayo Clin Proc; 1988 Jul; 63(7):707-17. PubMed ID: 2898572 [TBL] [Abstract][Full Text] [Related]
14. Clinical value of thyrotropin binding inhibiting immunoglobulins (TBII) assay in hyperthyroidism. Duron F; Talbot JN; Féron R; Aubert P; Milhaud G Biomed Pharmacother; 1987; 41(7):383-8. PubMed ID: 2895672 [TBL] [Abstract][Full Text] [Related]
15. [Clinical value of the determination of TSH-binding inhibitory immunoglobulins (TBII) by a radioreceptor assay]. Heberling HJ; Bierwolf B; Lohmann D Dtsch Z Verdau Stoffwechselkr; 1986; 46(5):301-6. PubMed ID: 2879721 [TBL] [Abstract][Full Text] [Related]
16. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose. Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020 [TBL] [Abstract][Full Text] [Related]
17. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease]. Bojarska-Szmygin A; Ciechanek R Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154 [TBL] [Abstract][Full Text] [Related]
18. Thyroid stimulating immunoglobulin in Graves' disease. Luttrell BM; Hales IB Aust N Z J Med; 1981 Jun; 11(3):293-8. PubMed ID: 6170289 [TBL] [Abstract][Full Text] [Related]
19. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre. Wallaschofski H; Kuwert T; Lohmann T Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319 [TBL] [Abstract][Full Text] [Related]
20. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report. Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]